Melatonin in sleep disorders.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | neutral | sleep-wake cycle | - | - | is the main hormone involved in the control of | #1 |
melatonin | neutral | insomnia | - | - | can be administered orally, which has led to interest in its use as a treatment for | #2 |
production of the hormone | decrease | poor sleep quality | - | - | decreases with age, in inverse correlation with the frequency of | #3 |
melatonin deficit | neutral | sleep disorders | - | - | is at least partly responsible for | #4 |
Treating this age-related deficit | increase | sleep quality | patients as they age | - | would therefore appear to be a natural way of restoring | #5 |
this substitutive therapy | no change | - | - | no significant change | little scientific evidence is available that supports any benefit of | #6 |
Melatonin is the main hormone involved in the control of the sleep-wake cycle. It is easily synthesisable and can be administered orally, which has led to interest in its use as a treatment for insomnia. Moreover, as production of the hormone decreases with age, in inverse correlation with the frequency of poor sleep quality, it has been suggested that melatonin deficit is at least partly responsible for sleep disorders. Treating this age-related deficit would therefore appear to be a natural way of restoring sleep quality, which is lost as patients age. However, despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy. Furthermore, the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined. This review addresses the physiology of melatonin, the different pharmaceutical preparations, and data on its clinical usefulness.